| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.8 |
| mRNA | pitstop2 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.041 | 0.8 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0088 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.016 | 0.8 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | selumetinib:JQ-1 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0088 | 0.8 |